Tell Your Idaho State Senator to Support Cancer Patients With SB 1034
Dear [Decision Maker],
This Monday, March 4th the Idaho State Senate is set to have a third reading of SB 1034, a bill which would correct an insurance benefit design inequality that causes patients to pay more out-of-pocket for orally administered or self-injected anticancer medications taken at home than for those administered in a hospital setting. Despite the nearly identical cost to insurers, anticancer treatments taken at home are placed on a prescription benefit that requires co-insurance at rates as high as 30% of the cost of the drug, while traditional IV therapy is administered at a hospital or clinic with a low $20-50 co-pay through a medical benefit. Some patients pay thousands of dollars a month before they reach their out-of-pocket max on their insurance due to this inequality. SB 1034 would fix this problem by requiring insurers to cover these take-home anticancer medications in the same way as they do for traditional IV chemotherapy. Insurers cannot raise the price of professionally administered treatment to comply with this bill.
Sincerely,[Your Name] [Your Address] [City, State ZIP][Your Email]